Compare BWMN & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | VOGX |
|---|---|---|
| Founded | 1995 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.6M | 482.8M |
| IPO Year | 2021 | 2026 |
| Metric | BWMN | VOGX |
|---|---|---|
| Price | $42.79 | $18.89 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $43.00 | N/A |
| AVG Volume (30 Days) | ★ 345.3K | 100.8K |
| Earning Date | 11-04-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 329.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $490,017,000.00 | N/A |
| Revenue This Year | $21.26 | N/A |
| Revenue Next Year | $18.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.88 | N/A |
| 52 Week Low | $25.07 | $14.56 |
| 52 Week High | $45.83 | $38.41 |
| Indicator | BWMN | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 80.78 | 37.39 |
| Support Level | $42.39 | N/A |
| Resistance Level | $43.14 | $36.96 |
| Average True Range (ATR) | 0.08 | 3.08 |
| MACD | -0.19 | -1.07 |
| Stochastic Oscillator | 71.25 | 21.09 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.